Literature DB >> 19773529

Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications.

Lawrence Toll1, Taline V Khroyan, Willma E Polgar, Faming Jiang, Cris Olsen, Nurulain T Zaveri.   

Abstract

The nociceptin receptor (NOPr), a member of the opioid receptor family, is a target for the treatment of pain and drug abuse. Nociceptin/orphanin FQ (N/OFQ), the endogenous peptide for NOPr, not only modulates opioid antinociception, but also blocks the rewarding effects of several abused drugs, such as morphine, cocaine, and amphetamine. We hypothesized that NOPr agonists, with bifunctional activity at the mu-opioid receptor (MOPr), may function as nonaddicting analgesics or as drug abuse medications. Bifunctional small-molecule NOPr agonists possessing different selectivities and efficacies at MOPr were evaluated in an acute thermal antinociception assay, and for their ability to induce conditioned place preference (CPP) and their effect on morphine-induced CPP. 1-(1-Cyclooctylpiperidin-4-yl)-indolin-2-one) (SR14150), a high-affinity NOPr partial agonist, with low MOPr affinity and efficacy, produced analgesia that was naloxone-reversible. SR14150 did not induce CPP alone, nor did it attenuate morphine-induced CPP. 3-Ethyl-1-(1-(4-isopropylcyclohexyl)piperidin-4-yl)-indolin-2-one (SR16507), which has high affinity for both NOPr and MOPr, full agonist activity at NOPr, and partial agonist activity at MOPr, was also a potent analgesic and produced CPP alone, but also modestly attenuated morphine CPP. 1-(1-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)piperidinl-4-yl)-indolin-2-one (SR16835), a NOPr full agonist and low-affinity MOPr partial agonist, was not antinociceptive, did not produce CPP alone, but attenuated morphine CPP. Our results suggest that NOPr full-agonist activity is required to modulate opioid-induced reward, whereas a bifunctional NOPr/MOPr partial agonist profile may be suitable as a nonaddicting analgesic. The opioid-modulating effects of the NOPr ligands may be used effectively to produce better medications for treatment of drug abuse and pain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19773529      PMCID: PMC2784720          DOI: 10.1124/jpet.109.157446

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  40 in total

1.  Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist.

Authors:  P Huang; G B Kehner; A Cowan; L Y Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2001-05       Impact factor: 4.030

2.  Influence of the selective ORL1 receptor agonist, Ro64-6198, on rodent neurological function.

Authors:  G A Higgins; A J Grottick; T M Ballard; J G Richards; J Messer; H Takeshima; M Pauly-Evers; F Jenck; G Adam; J Wichmann
Journal:  Neuropharmacology       Date:  2001-07       Impact factor: 5.250

3.  Effects of nociceptin/orphanin FQ receptor (NOP) agonist, Ro64-6198, on reactivity to acute pain in mice: comparison to morphine.

Authors:  David Reiss; Juergen Wichmann; Hiroshi Tekeshima; Brigitte L Kieffer; Abdel-Mouttalib Ouagazzal
Journal:  Eur J Pharmacol       Date:  2007-10-25       Impact factor: 4.432

4.  Expression of orphanin FQ and the opioid receptor-like (ORL1) receptor in the developing human and rat brain.

Authors:  C R Neal; H Akil; S J Watson
Journal:  J Chem Neuroanat       Date:  2001-11       Impact factor: 3.052

5.  SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice.

Authors:  Taline V Khroyan; Nurulain T Zaveri; Willma E Polgar; Juan Orduna; Cris Olsen; Faming Jiang; Lawrence Toll
Journal:  J Pharmacol Exp Ther       Date:  2006-11-28       Impact factor: 4.030

6.  Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system.

Authors:  Roberto Ciccocioppo; Daina Economidou; Roberto Rimondini; Wolfgang Sommer; Maurizio Massi; Markus Heilig
Journal:  Biol Psychiatry       Date:  2006-03-14       Impact factor: 13.382

7.  Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys.

Authors:  Mei-Chuan Ko; James H Woods; William E Fantegrossi; Chad M Galuska; Jürgen Wichmann; Eric P Prinssen
Journal:  Neuropsychopharmacology       Date:  2009-03-11       Impact factor: 7.853

8.  Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.

Authors:  Taline V Khroyan; Willma E Polgar; Faming Jiang; Nurulain T Zaveri; Lawrence Toll
Journal:  J Pharmacol Exp Ther       Date:  2009-08-27       Impact factor: 4.030

9.  The mu opioid receptor is involved in buprenorphine-induced locomotor stimulation and conditioned place preference.

Authors:  Paul Marquez; Ramkumarie Baliram; Brigitte L Kieffer; Kabirullah Lutfy
Journal:  Neuropharmacology       Date:  2007-01-20       Impact factor: 5.250

10.  Activities of mixed NOP and mu-opioid receptor ligands.

Authors:  B Spagnolo; G Calo; W E Polgar; F Jiang; C M Olsen; I Berzetei-Gurske; T V Khroyan; S M Husbands; J W Lewis; L Toll; N T Zaveri
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

View more
  40 in total

1.  The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward.

Authors:  Taline V Khroyan; Willma E Polgar; Gerta Cami-Kobeci; Stephen M Husbands; Nurulain T Zaveri; Lawrence Toll
Journal:  J Pharmacol Exp Ther       Date:  2010-12-21       Impact factor: 4.030

2.  Small-molecule nociceptin receptor agonist ameliorates mast cell activation and pain in sickle mice.

Authors:  Derek Vang; Jinny A Paul; Julia Nguyen; Huy Tran; Lucile Vincent; Dennis Yasuda; Nurulain T Zaveri; Kalpna Gupta
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

Review 3.  Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.

Authors:  Nurulain T Zaveri
Journal:  J Med Chem       Date:  2016-03-14       Impact factor: 7.446

4.  Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption.

Authors:  Marsida Kallupi; Qianwei Shen; Giordano de Guglielmo; Dennis Yasuda; V Blair Journigan; Nurulain T Zaveri; Roberto Ciccocioppo
Journal:  Addict Biol       Date:  2017-06-21       Impact factor: 4.280

5.  Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.

Authors:  V Blair Journigan; Willma E Polgar; Taline V Khroyan; Nurulain T Zaveri
Journal:  Bioorg Med Chem       Date:  2014-03-05       Impact factor: 3.641

6.  Nociceptin receptor activation does not alter acquisition, expression, extinction and reinstatement of conditioned cocaine preference in mice.

Authors:  G C Sartor; S K Powell; H J Wiedner; C Wahlestedt; S P Brothers
Journal:  Brain Res       Date:  2015-12-03       Impact factor: 3.252

7.  Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.

Authors:  Devki D Sukhtankar; Nurulain T Zaveri; Stephen M Husbands; Mei-Chuan Ko
Journal:  J Pharmacol Exp Ther       Date:  2013-05-07       Impact factor: 4.030

8.  A Novel and Selective Nociceptin Receptor (NOP) Agonist (1-(1-((cis)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol (AT-312) Decreases Acquisition of Ethanol-Induced Conditioned Place Preference in Mice.

Authors:  Nurulain T Zaveri; Paul V Marquez; Michael E Meyer; Willma E Polgar; Abdul Hamid; Kabirullah Lutfy
Journal:  Alcohol Clin Exp Res       Date:  2018-01-19       Impact factor: 3.455

9.  Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms.

Authors:  Marta Sobczak; Gerta Cami-Kobeci; Maciej Sałaga; Stephen M Husbands; Jakub Fichna
Journal:  Eur J Pharmacol       Date:  2014-05-06       Impact factor: 4.432

Review 10.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.